YUNNAN BAIYAO GROUP CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 52.45 CNY | +2.54% |
|
+2.32% | +6.71% |
| 01/07 | Yunnan Baiyao Buys Rights on KA-1641 Drug | MT |
| 12/06 | Yunnan Baiyao Group Co.,Ltd Announces Board Appointments | CI |
ETFs positioned on Yunnan Baiyao Group Co.,Ltd
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.68% | 1 M€ | -23.18% | - | |
| 1.32% | 2 M€ | -14.14% | ||
| 1.18% | 4 M€ | -2.96% | ||
| 0.13% | 35 M€ | -5.85% | - | |
| 0.11% | 2 M€ | -1.96% | - | |
| 0.10% | 4 M€ | -11.56% | ||
| 0.05% | 11 M€ | +6.19% | ||
| 0.01% | 4 M€ | -4.41% | - | |
| 0.01% | 152 M€ | +7.69% | - | |
| 0.01% | 451 M€ | +8.73% | - | |
| 0.01% | 2,838 M€ | +10.59% | - | |
| 0.01% | 114 M€ | +5.88% | - | |
| 0.00% | 35 M€ | +4.82% | - | |
| 0.00% | 7 M€ | +3.59% | - | |
| 0.00% | 32 M€ | +4.18% | - | |
| 0.00% | 36 M€ | +9.99% | - | |
| 0.00% | 414 M€ | +11.25% | - | |
| 0.00% | 40 M€ | +6.34% | - | |
| 0.00% | 324 M€ | +7.85% | - |
Yunnan Baiyao Group Co., Ltd. specializes in the development, manufacturing and marketing of pharmaceutical products. The group proposes primarily traditional medicine products, phytobiological products, body care products, antibiotics and anti-inflammatory.
China accounts for 98.9% of net sales.
Sector
Pharmaceuticals
Calendar
29/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
52.45
CNY
Average target price
65.01
CNY
Spread / Average Target
+23.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.71% | 1.29TCr | |
| +56.86% | 82TCr | |
| +44.76% | 64TCr | |
| -6.57% | 35TCr | |
| +17.32% | 32TCr | |
| +9.94% | 30TCr | |
| +15.08% | 24TCr | |
| +1.23% | 22TCr | |
| +12.78% | 22TCr | |
| +7.98% | 17TCr |
- Stock Market
- Equities
- 000538 Stock
- Funds and ETFs Yunnan Baiyao Group Co.,Ltd
